Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.

Huang, Chengchi; Ji, Liyang; Kaur, Avinash; Tian, Hong; Waduge, Prabuddha; Webster, Keith A; Li, Wei

Huang, Chengchi; Ji, Liyang; Kaur, Avinash; Tian, Hong; Waduge, Prabuddha; Webster, Keith A; Li, Wei.

Afiliação

Huang C; Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Ji L; Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Kaur A; Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Tian H; Everglades Biopharma, LLC, Houston, TX 77098, USA.
Waduge P; Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Webster KA; Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Li W; Everglades Biopharma, LLC, Houston, TX 77098, USA.

Biomedicines ; 11(7)2023 Jul 06.

Article em En | MEDLINE | ID: mdl-37509549

Palavras-chave

age-related macular degeneration; anti-Scg3 gene therapy; anti-VEGF gene therapy; choroidal neovascularization; disease-targeted gene therapy; gene therapy; secretogranin III (Scg3); vascular endothelial growth factor (VEGF)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Biomedicines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google